A Novel LC-MS/MS Method for the Direct Analysis of Underivatized Amino Acids In Human Plasma

Shun-Hsin Liang, Justin Steimling; Restek Corporation

Abstract & Introduction

Amino acids are critical molecules for biological function as they serve as building blocks of peptides/proteins and intermediates of various metabolic pathways (e.g., urea cycle and citric acid cycle). Amino acids profiling in plasma is an important tool for the diagnosis of metabolic disorders, especially for inborn errors of metabolism. A fast and accurate large panel amino acids analysis is critical not only for disorder identification but also for continued monitoring and assessment of nutritional status of patients and treatment plans. Traditionally, amino acids were analyzed by either post-column or precolumn derivatization methodologies. The major shortcomings of these approaches are long chromatographic cycling time (post-column derivatization) and poor chromatographic separation (pre-column derivatization) for comprehensive amino acid quantification in plasma. The relative lack of applications for direct analysis of underivatized amino acids by LC-MS/MS is due to limited chromatographic retention and insufficient detection sensitivity. In this study, a simple workflow was developed and implemented for accurate quantification of a large panel of 45 amino acids in human plasma. A fast chromatographic analysis (13 minutes) was achieved using a unique hybrid HILIC/ion exchange column for high-throughput amino acids profiling in plasma.

Calibration Standard Preparation

Calibration standards were prepared at the range of 1-500 µmol/L in 1x PBS solution. An aliquot of 25 μ L of calibration standard was mixed with 2.5 μ L of 30% sulfosalicylic acid solution, 2 µL of IS working solution, and 225 µL of mobile phase B for injection analysis.

Results & Discussion

(1) Chromatographic Performance: A fast chromatographic method was established for simultaneous analysis of 45 amino acids with a 13-minute total cycling time (Figure 1a, control plasma L2). The isobaric compounds leucine/isoleucine/allo-isoleucine (Figure 1b) and alanine/sarcosine (Figure 1c) are chromatographically separated for definitive and accurate quantification in plasma. The chromatographic retention of 3 analytes, β -aminoisobutyric acid, γ -aminobutyric acid, and β alanine, is sensitive to the salting condition in final injection solution. Therefore, PBS was added to the standard solution to match the salting condition in plasma sample solution and resulted in consistent retention time of these 3 compounds between standard and sample solutions.

- (2) Linearity: Various calibration ranges were determined considering different MS detection sensitivity and the suitability of diagnostic measurement of all 45 analytes (see Table 2). All compounds showed acceptable linearity with r² value > 0.990 and deviations <20% with quadratic regression (1/x weighted). While the highest quantifiable concentration of 500 µmol/L is suitable for most of the analytes, it is necessary to dilute the plasma sample for the analysis of glutamine and alanine due to their relatively higher physiological concentration of > 500 μ mol/L.
- (3) Accuracy & Precision: Three control plasma samples containing low to high concentration of all 45 analytes were used to evaluate the method accuracy and precision. The acceptable criteria for method accuracy is to have measured concentration within the specified concentration range. A total of 3 batches of analyses were performed on different days. To compensate for the plasma matrix effect, 28 isotopes were carefully examined to act as the best fitted internal standards for

Plasma Sample Preparation

An aliquot of 50 μ L of control plasma was mixed with 5 μ L of 30% sulfosalicylic acid solution for protein precipitation. Following centrifugation, took out 27.5 µL of clear supernatant and mixed with 2 μ L of IS working solution and 225 μ L of mobile phase B for injection analysis.

Methods

Table 1: Analytical Conditions for Waters Xevo TQ-S with Acquity UPLC

Analytical Column	Raptor Polar X 2.7 μm 100 mm x 2.1 mm (Restek Cat.# 9311A12)									
Guard Column	Raptor Polar X EXP Guard Column Cartridge 2.7um, 5 mm x 2.1 mm (Cat.# 9311A0252)									
Mobile Phase A	0.5% formic acid, 1mM ammonium formate in water									
Mobile Phase B	0.5% formic acid, 1mM ammonium formate in 90:10 acetonitrile:water									
Gradient	Time (min)	%B								
	0.00	96								
	2.00	96								
	10.00	30								
	10.01	5								
	11.00	5								
	11.01	96								
	13.00	96								
Flow Rate	0.3 mL/min									
Injection Volume	5 μL									
Column Temp.	35°C									
Ion Mode	Scheduled MRM in positive ESI									

the quantification of various analytes. Table 2 shows the accuracy and precision results averaged from the collection of all 3 batches of data (n=9) and internal standards used for the quantification of each analyte. The method accuracy was demonstrated with concentration values of within the nominal range for all 45 analytes. The %RSD was <20% indicating acceptable method precision.

Figure 1: Analysis of Control Plasma



Table 2: Accuracy & Precision Analysis

				Control Level 1		Control Level 2		Control Level 3						Control Level 1		Control Level 2		Control Level 3	
				Nominal				Nominal					Linearity	Nominal Conc.	Average Conc.	Nominal Conc.	Average Conc.	Nominal Conc.	Average Conc.
	.		Linearity	Conc.	Average Conc.	Nominal Conc.	Average Conc.	Conc.	Average Conc.		Retention		Range	Range	(µmol/L)	Range	(µmol/L)	Range	(μmol/L)
Analutaa	Retention	IC	Range	Range	(µmol/L)	Range	(µmol/L)	Range	(µmol/L)	Analytes	Time	IS	(µmol/L)	(µmol/L)	(%RSD)	(µmol/L)	(%RSD)	(µmol/L)	(%RSD)
Analytes	1.02	IS A satultuma ina d2			(%KSD)					Homocystine	6.20	Homocystine-d8	1 - 500	3.29 - 4.93	3.60 (9.17)	10.5 - 15.8	12.8 (5.69)	18.0 - 27.0	22.0 (4.71)
etyityrosine	1.83	Acetyityrosine-d3	0.5 - 250	4.10 - 6.15	4.84 (9.76)	32.5 - 48.8	40.5 (9.76)	58.5 - 87.7	/3.9 (15.1)	Hydroxylysine	4.84	Threonine ¹³ C ₄ ¹⁵ N	5 - 500	3.97 - 5.96	5.50 (7.60)	14.3 - 21.4	16.58 (11.2)	24.3 - 36.5	28.4 (14.2)
enosylhomocystelne	5.30		2.5 - 250	2.77 - 4.16	3.16 (15.0)	17.8 - 26.7	20.4 (15.4)	32.5 - 48.8	42.9 (9.98)	Hydroxyproline	5.26	Threonine ¹³ C ₄ ¹⁵ N	5 - 500	7.94 - 11.9	10.1 (14.2)	72.8 - 109	97.52 (8.40)	136 - 204	198 (5.02)
nine	4.86	Alanine ¹³ C ₃ ¹³ N	5 - 500	159 - 239	191 (15.0)	524 - 786	655* (20.0)	890 - 1334	979* (19.4)	Allo-isoleucine	3.77	Methionine ¹³ C ₅ ¹⁵ N	0.5 - 250	2.86 - 4.29	3.55 (3.12)	65.5 - 98.2	79.15 (4.56)	128 - 192	150 (5.87)
	2.52	IS-Alanine-d4	1 - 500	10.4 - 15.5		42.7 - 64.0	47.9 (3.12)	74.0 - 111	81.1 (3.01)	Isoleucine	3.60	Isoleucine ¹³ C ₆ ¹⁵ N	5 - 500	18.4 - 27.6	20.1 (3.12)	143 - 215	164.41 (3.01)	260 - 389	282 (2.69)
Aminoadipic acid	5.53	Asparagine-d3	1 - 500	4.98 - 7.46	5.74 (7.53)	9.92 - 14.9	11.2 (6.75)	14.7 - 22.1	17.9 (11.7)	Leucine	3.40	Leucine ¹³ C ₆ ¹⁵ N	5 - 500	40.2 - 60.3	43.3 (2.57)	239 - 358	288.87 (4.37)	444 - 666	512* (4.67)
Aminobutyric acid	4.57	a-Aminobutyric acid-d	2 1 - 500	3.69 - 5.54	4.47 (11.4)	39.5 - 59.2	52.1 (10.9)	/3.6 - 110	97.7 (7.43)	Lysine	4.68	Lysine ¹³ C ₆ ¹⁵ N ₂	1 - 500	21.9 - 32.9	28.2 (5.79)	231 - 346	315.89 (4.13)	436 - 655	621* (4.61)
minoisobutyric acid	2 27	p-Aminoisobutyric acid-d3	1 - 500	3 82 - 5 73	4 40 (9 85)	17.0 - 25.5	19 2 (6 10)	297-445	35 3 (7 75)	Methionine	4.15	Methionine ¹³ C ₅ ¹⁵ N	1 - 500	6.80 - 10.2	7.46 (5.29)	64.8 - 97.1	72.02 (3.83)	121 - 181	139 (2.32)
minobutyric acid	2.27	v-Aminobutyric acid-d	4 1 - 500	3 79 - 5 69	4.75 (5.35)	7 98 - 12 0	9 60 (3 45)	12.0 - 17.9	14 1 (5 60)	1-Methylhistidine	4.62	1-Methylhistidine-d3	1 - 500	2.06 - 3.08	2.52 (8.18)	6.17 - 9.25	7.12 (9.84)	10.3 - 15.4	12.4 (9.84)
serine	4.67	Histiding 13C 15N	1 - 500	3.85 - 5.77	4.73 (3.33)	7.55 - 11.5	10 8 (5 82)	11 5 - 17 3	15 9 (7 71)	3-Methylhistidine	4.68	Histidine ¹³ C ₆ ¹⁵ N ₃	5 - 500	5.82 - 8.73	8.03 (8.31)	36.2 - 54.3	43.81 (10.2)	66.3 - 99.5	85.1 (4.10)
tinine	4.07	Argining ${}^{13}C$ ${}^{15}N$	1 - 500	8 62 - 17 9	9 55 (11 5)	124 - 186	133 (3.60)	227 - 256	257 (2.22)	Ornithine	4.72	Lysine ¹³ C _c ¹⁵ N ₂	5 - 500	13.6 - 20.4	15.2 (3.13)	161 - 242	168.76 (4.35)	301 - 452	322 (5.76)
ginine gininosuccinic acid	7 41	$\frac{13}{15}$	0 5 - 250	2 35 - 3 53	2 96 (13 3)	597-896	72 3 (11 1)	115 - 172	141 (7 99)	Phenylalanine	3.53	Phenylalanine ¹³ C _o ¹⁵ N	1 - 500	32.2 - 48.3	36.5 (3.38)	248 - 373	297.96 (1.80)	461 - 692	547* (4.31)
aragine	5 5/	Asparagine $d_6 N_2$	1 - 500	21.4 - 32.1	21.3 (2.46)	97.0 - 145	1/12 (1 20)	172 - 259	250 (2.22)	, Phosphoethanolamine	7.32	Cystine ¹³ C ₆ ¹⁵ N ₂	5 - 500	8.53 - 12.8	9.64 (12.2)	57.4 - 86.1	64.32 (9.09)	105 - 158	127 (9.93)
partic acid	9.94 8.00	Aspartic Acid ¹³ C ¹⁵ N	1 - 500	19 5 - 27 7	19.2 (1.82)	101 - 152	105 (3 54)	182 - 274	189 (2.89)	Pipecolic acid	4.60	Pipecolic acid-d9	0.5 - 250	1.62 - 2.43	1.85 (9.98)	13.4 - 20.0	17.25 (8.08)	24.6 - 36.9	31.0 (7.45)
	4.67	Histiding 13C 15N	1 - 500	7 69 - 11 5	10.3 (9.66)	19.0 - 29.2	103(3.54)	20.2 - 42.8	36 6 (10 2)	Proline	4.89	Proline ¹³ C ₅ ¹⁵ N	1 - 500	50.7 - 76.1	58.6 (4.05)	268 - 403	322.45 (3.46)	482 - 722	578* (4.99)
rullino	5.61	Asparagina d2	5 500	12 7 10 1	15.6 (12.0)	22 9 126	23.7 (10.1)	152 220	161 (1 62)	Sarcosine	5.05	Threonine ¹³ C ₄ ¹⁵ N	1 - 500	3.29 - 4.94	4.00 (7.35)	13.5 - 20.3	19.59 (6.51)	23.7 - 35.5	34.8 (4.19)
tathionine	6.75	Asparagine-us	1 - 500	12.7 - 13.1	5 76 (6 47)	20.1 - 20.1	23 1 (8 07)	25.2 - 52.0	101 (1.03)	Serine	5.46	Serine ¹³ C, ¹⁵ N	5 - 500	102 - 153	126 (3.65)	295 - 443	383.86 (6.51)	484 - 726	627* (5.89)
tino	6.00	$\frac{\text{Glutallic Aclustic}_{5} = 1}{\text{Cyctine 13C} 15\text{N}}$	0 5 250	9 54 12 9	10.2 (0.47)	62 7 94 0	79 9 (6 22)	116 174	144 (9.05)	Taurine	4.65	Taurine-d4	5 - 500	14.7 - 22.1	18.2 (6.28)	173 - 260	234.74 (3.51)	325 - 488	433 (6.26)
	1.06	Ethanolomina d4	0.5 - 250 E 2E0	0.54 - 12.0	10.3(9.50)	02.7 - 94.0		10 - 174	144 (9.05) 206 (2.52)	Threonine	5.15	Threonine ¹³ C, ¹⁵ N	1 - 500	36.7 - 55.1	42.6 (2.76)	203 - 304	246.86 (7.01)	366 - 549	464 (4.16)
anoiamine	6.26	Clutomic Acid 13C 15N	<u>5 - 250</u>	12.3 - 10.4	13.2 (11.1) 52 7 (6 16)	30.5 - 140	125(11.3)	102 - 273	200 (3.33)	Tryptophan	3.31	ß-Alanine-d4	1 - 500	13.5 - 20.2	16.9 (11.5)	88.4 - 133	107.52 (7.72)	158 - 237	188 (10.3)
	0.20		1 - 500	45.8 - 08.7	55.7 (0.10)	304 - 450	555 (8.12)	555 - 829 1200 1914	595 (8.49)	Tvrosine	4.27	Tyrosine ¹³ C ₂ ¹⁵ N	1 - 500	22.3 - 33.5	25.4 (5.35)	129 - 194	148.82 (2.58)	232 - 348	264 (3.40)
	5.43	Giulamine-05	25 500	280 - 429	3/1 (3.58)	748 - 1122	9/5 [*] (5.40)	1209 - 1814	158/ ° (8.40)	Valine	4.27	Valine ¹³ C. ¹⁵ N	1 - 500	74.4 - 112	91.3 (6.73)	256 - 384	318.69 (7.67)	442 - 664	532* (9.56)
	5.19		25 - 500	154 - 231		51/ - //5	013" (7.54)	804 - 1295	332 (10.3)				_ 000			200 001			
	4.65	Histidine ¹³ C ₆ ¹³ N ₃	1 - 500	35.9 - 53.9	47.6 (5.27)	121 - 182	15/ (/.2/)	210 - 316	266 (4.35)	*Concentration is outside of the calibration range 8.7 (2.69)									
mocitrulline	5.43	Glutamine-d5	2.5 - 250	7.88 - 11.8	9.87 (2.05)	22.6 - 33.9	31.3 (3.83)	37.1 - 55.6	53.7 (2.69)										

Standard and Control Plasma Materials

Two standard mixture solutions (A6282 & A6407) containing a total of 28 amino acids and 17 solid standards were all obtained from Sigma-Aldrich. A stock standard solution containing 45 amino acids was prepared in phosphate buffered saline (1x PBS) solution at 250-500 µmol/L. The internal standard working solution was prepared by mixing a stock solution of 17 isotopically labeled amino acids (MSK-A2-S, Cambridge Isotope Laboratories) with 12 individual deuterium isotopes of α -aminobutyric acid, β -aminoisobutyric acid, γ -aminobutyric acid, β -alanine, N-acetyltyrosine, asparagine, ethanolamine, glutamine, homocystine, 1-methylhistidine, pipecolic acid, and taurine (CDN) *Isotopes*) in water at 125-250 µmol/L. MassChrom[®] Amino Acid Analysis Plasma Control Level I (0471), II (0472), and III (0473) were obtained from Chromsystems.

PATENTS & TRADEMARKS

Restek patents and trademarks are the property of Restek Corporation. (See www.restek.com/Patents-Trademarks for full list.) Other trademarks in Restek literature or on its website are the property of their respective owners. Restek registered trademarks are registered in the U.S. and may also be registered in other countries.

This method has been developed for research use only; it is not suitable for use in diagnostic procedures without further evaluation.

Conclusions

It was demonstrated that simultaneous measurement of 45 amino acids in plasma can be achieved with a simple sample preparation procedure and a fast 13-minute LC-MS/MS analysis using the Raptor Polar X column. The established method provides high-throughput and accurate determination for amino acid profiling in human plasma.



Pure Chromatography

www.restek.com